医学
危险系数
肿瘤科
前列腺癌
内科学
背景(考古学)
荟萃分析
科克伦图书馆
临床试验
置信区间
癌症
生物
古生物学
作者
Carlo Messina,Emilio Francesco Giunta,Alessio Signori,Sara Elena Rebuzzi,Giuseppe Luigi Banna,Akash Maniam,Sebastiano Buti,Carlo Cattrini,Giuseppe Fornarini,Matteo Bauckneht,Alastair Greystoke,Ruth Plummer,Christoph Oing,Pasquale Rescigno
标识
DOI:10.1016/j.euo.2023.07.013
摘要
Abstract
Context
PARP inhibitors (PARPi) are established treatments for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) deficiency after androgen receptor signalling inhibitor (ARSI) failure. New PARPi + ARSI combinations have been tested in all comers, although their clinical relevance in HRR-proficient tumours remains uncertain. Objective
To quantitatively synthesise evidence from randomised trials assessing the efficacy and safety of PARPi + ARSI combinations for first-line treatment of mCRPC. Evidence acquisition
We searched the PubMed, EMBASE, SCOPUS, and Cochrane Library databases up to February 28, 2023. Randomised controlled trials (RCTs) comparing PARPi + ARSI versus placebo + ARSI for first-line treatment of mCRPC were eligible. Two reviewers independently performed screening and data extraction and assessed the risk of bias, while a third reviewer evaluated the eligibility criteria. Evidence synthesis
Overall, three phase 3 RCTs were included in the systematic review: PROPEL, MAGNITUDE, and TALAPRO-2. A total of 2601 patients with mCRPC were enrolled. Two of these trials (PROPEL and TALAPRO-2) assessed the radiographic progression-free survival benefit of PARPi + ARSI for first-line treatment of mCRPC, independent of HRR status. The pooled hazard ratio was 0.62 (95% confidence interval 0.53–0.72). The pooled hazard ratio for overall survival was 0.84 (95% confidence interval 0.72–0.98), indicating a 16% reduction in the risk of death among patients who received the combination. Conclusions
Results from this meta-analysis support the use of ARSI + PARPi combinations in biomarker-unselected mCRPC. However, such combinations might be less clinically relevant in HRR-proficient cancers, especially considering the change in treatment landscape for mCRPC. Patient summary
We looked at outcomes from trials testing combinations of two classes of drugs (PARP inhibitors and ARSI) in advanced prostate cancer. We found that these combinations seem to work regardless of gene mutations identified as biomarkers of response to PARP inhibitors when used on their own.
科研通智能强力驱动
Strongly Powered by AbleSci AI